Abstract: Described are procedures and intermediates for the preparation of guadecitabine, and guadecitabine salts and solid state forms thereof.

Abstract: Synthesis of mycophenolate mofetil (1), where R1=2-(-morpholinyl)ethyl and R2=hydrogen atom, includes reaction of mycophenolic acid with 4-(2-hydroxyethyl)morpholine in a suitable solvent under azeotropic separation of water.

Abstract: Pharmaceutical compositions especially for internal application which create lyotropic liquid crystals when in contact with aqueous phase. The pharmaceutical compositions consist of: A hydrophobic active ingredient with immunomodulatory effect from a group of N-methylated cyclic undecapeptides or macrolide antibiotics, in quantity 1-35 weight % in a carrier medium containing B at least one absorption promoter allowing for contact of the drug with a biological membrane or passing of the drug through in quantity 1-40 weight %, C nonlipidic vehicle containing at lest one of the below mentioned substances: C1 surfactant or mixed surfactant with HLB>9, in quantity 1-80 weight % C2 lipophilic solvent from group of higher fatty alcohols in quantity 1-30 weight % C3 at least one cosurfactant in quantity 1-50 weight %, while a ratio among the individual components of the product is A:B:C=1:0.5-4:5-8.

Abstract: Provided are therapeutic compositions which provide high bioavailability of the active ingredients from the group of cyclosporin, at the same time permitting concentrations in dosage forms higher than 10%.

Abstract: Provided are therapeutic compositions which provide high bioavailability of the active ingredients from the group of cyclosporin, at the same time permitting concentrations in dosage forms higher than 10%.

Abstract: Therapeutical compositions comprising from 0.1 to 20% by weight of a cyclosporin and a vehicle comprising from 1 to 60% by weight of polyethers constituted by, preferably, substances like ethoxy diglycol or polyethylene glycols 300 to 600 and/or substances like preferably dimethyl isosorbide, dimethyl isoidide and dimethyl isomannide, and from 1 to 60% by weight of a mixture of glyceryl monoesters of C.sub.8 -C.sub.22 fatty acids and hexaglyceryl to pentadecaglyceryl monoesters of C.sub.8 -C.sub.22 fatty acids in a ratio of 1:2 to 1:6. The therapeutical compositions preferably additionally comprise further adjuvants like anti-oxidants, preserving agents and stabilizers, flavoring agents, thickening agents and diluents. The compositions for external use preferably additionally comprise lipoaminoacids.

Abstract: Process for the preparation of 3,14.beta.-dihydroxy-17-normorphinan ##STR1## A suitable economic process for the preparation of 3,14.beta.-dihydroxy-17-normorphinan of a general formula (I) is being solved, which is a key intermediate of a semisynthetic synthesis of an effective analgesic of Butorphanol from thebaine.Synthesis includes a two step N-demethylation, and concerted dephenoxylation of 4-phenoxy-14.beta.-hydroxy-3-methoxymorphinan in the first step by means of a chloroformate, then, in the second step, by means of sodium action in a liquid ammonia, and by means of the following O-demethylation under action of a complex of aluminium chloride - dialkylsulfide.